Conduta terapêutica em pacientes com doença pulmonar obstrutiva crônica: monoterapia ou terapia cominada? / Therapy for chronic obstructive pulmonary disease patients: monotherapy or combination therapy?
Rev. Soc. Bras. Clín. Méd
;
18(1): 25-31, marco 2020.
Article
in Portuguese
| LILACS
| ID: biblio-1361296
RESUMO
Objetivo:
Comparar a dupla terapia broncodilatadora com glicopirrônio mais indacaterol à monoterapia com glicopirrônio em pacientes portadores de doença pulmonar obstrutiva crônica.Métodos:
Estudo clínico prospectivo, unicêntrico, controlado, cruzado, randomizado e duplo-cego realizado com 14 pacientes com diagnóstico de doença pulmonar obstrutiva crônica grau II. Os participantes receberam cada um dos tratamentos durante 30 dias. Antes de cada terapia, realizou-se período de wash-out por 7 dias, com broncodilador de curta ação. Antes e após cada intervenção, os pacientes passaram por exame de espirometria e responderam ao questionário COPD Assessment Test.Resultados:
Observou-se melhora na função pulmonar medida por meio do volume expiratório forçado no primeiro segundo de 19mL (±36) para a monoterapia e 87mL (±33) para a terapia dupla. O ganho foi de 67mL (p=0,042) da associação dos medicamentos em relação ao glicopirrônio isolado. A melhora na qualidade de vida, medida a partir das pontuações do questionário, foi de 4,7 (±8,9) pontos para a monoterapia e 5,2 (±11) pontos para a dupla terapia (p=0,08).Conclusão:
Ambos os tratamentos demonstram melhora na função pulmonar dos pacientes.ABSTRACT
Objective:
To compare dual bronchodilator therapy (Glycopyrronium with Indacaterol) versus Glycopyrronium monotherapy in patients with chronic obstructive pulmonary disease.Methods:
This was a prospective, unicentric, controlled, crossover, randomized, and double-blind clinical trial with 14 patients diagnosed with grade II chronic obstructive pulmonary disease. The participants received each treatment during the period of 30 days. Before each therapy, a 7-day wash-out period with a short-acting bronchodilator was instituted. Before and after each intervention, the patients underwent spirometry and answered the COPD Assessment Test questionnaire.Results:
An improvement in pulmonary function measured by forced expiratory volume during the first second of 19mL (±36) for monotherapy, and 87mL (±33) for dual therapy was observed. The gain was of 67mL (p=0.042) in the association of the drugs in relation to Glycopyrronium alone. The mean improvement in quality of life measured from the questionnaire scores was 4.7 (±8.9) points for monotherapy and 5.2 (± 11) points for dual therapy (p=0.08).Conclusion:
Both treatments show improvement in the patients' pulmonary function.
Full text:
Available
Index:
LILACS (Americas)
Main subject:
Bronchodilator Agents
/
Quinolones
/
Muscarinic Antagonists
/
Pulmonary Disease, Chronic Obstructive
/
Glycopyrrolate
/
Indans
Type of study:
Controlled clinical trial
/
Diagnostic study
/
Observational study
/
Risk factors
Limits:
Adult
/
Aged
/
Aged80
/
Female
/
Humans
/
Male
Language:
Portuguese
Journal:
Rev. Soc. Bras. Clín. Méd
Journal subject:
Therapeutics
Year:
2020
Type:
Article
Affiliation country:
Brazil
Institution/Affiliation country:
, Universidade Federal do Paraná/BR
Similar
MEDLINE
...
LILACS
LIS